Obesity and Diabetes Epidemics:

Cancer Repercussions
  • Anette Hjartåker
  • Hilde Langseth
  • Elisabete Weiderpass
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 630)


The prevalence of overweight (body mass index, BMI, between 25 and 30 kg/m2) and obesity (BMI of 30 kg/m2 or higher) is increasing rapidly worldwide, especially in developing countries and countries undergoing economic transition to a market economy. One consequence of obesity is an increased risk of developing type II diabetes.

Overall, there is considerable evidence that overweight and obesity are associated with risk for some of the most common cancers. There is convincing evidence of a positive association between overweight/obesity and risk for adenocarcinoma of the oesophagus and the gastric cardia, colorectal cancer, postmenopausal breast cancer, endometrial cancer and kidney cancer (renal-cell). Premenopausal breast cancer seems to be inversely related to obesity. For all other cancer sites the evidence of an association between overweight/obesity and cancer is inadequate, although there are studies suggesting an increased risk of cancers of the liver, gallbladder, pancreas, thyroid gland and in lymphoid and haematopoietic tissue.

Far less is known about the association between diabetes mellitus type I (also called insulin dependent diabetes mellitus or juvenile diabetes), type II diabetes (called non-insulin dependent diabetes mellitus or adult onset diabetes mellitus) and cancer risk. The most common type of diabetes mellitus, type II, seems to be associated with liver and pancreas cancer and probably with colorectal cancer. Some studies suggest an association with endometrial and postmenopausal breast cancer. Studies reporting on the association between type I diabetes mellitus, which is relatively rare in most populations and cancer risk are scanty, but suggest a possible association with endometrial cancer.

Overweight and obesity, as well as type II diabetes mellitus are largely preventable through changes in lifestyle. The fundamental causes of the obesity epidemic—and consequently the diabetes type II epidemic—are societal, resulting from an environment that promotes sedentary lifestyles and over-consumption of energy. The health consequences and economic costs of the overweight, obesity and type II diabetes epidemics are enormous. Avoiding overweight and obesity, as well as preventing type II diabetes mellitus, is an important purpose to prevent cancer and other diseases. Prevention of obesity and type II diabetes should begin early in life and be based on the life-long health eating and physical activity patterns. Substantial public investments in preventing overweight, obesity and type II diabetes mellitus are both appropriate and necessary in order to have a major impact on their adverse health effects including cancer.


Breast Cancer Pancreatic Cancer Cancer Risk Diabetes Type Breast Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Agency for Research on Cancer, World Health Organization. Weight control and physical activity. Vainio H, Bianchini F, editors. 2002. Lyon, IARC Press. IARC Handbooks of Cancer Prevention.Google Scholar
  2. 2.
    Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006; 1084:1–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Trevisan R, Vedovato M, Tiengo A. the epidemiology of diabetes mellitus. Nephrol Dial Transplant 1998; 13 Suppl 8:2–5.CrossRefPubMedGoogle Scholar
  4. 4.
    World Health Organization. Health topics. 2007;7-5-2007. Available on: Scholar
  5. 5.
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363(9403):157–163.CrossRefGoogle Scholar
  6. 6.
    World Health Organization. 22-4-2007. WHO Global InfoBase Online 2007. Available on: Scholar
  7. 7.
    Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295(13):1549–1555.CrossRefPubMedGoogle Scholar
  8. 8.
    World Health Organization. Diabetes Programme. WHO Country and Regional Data 2007. Available on: Scholar
  9. 9.
    International Diabetes Federation. Diabetes atlas. International Diabetes Federation-Diabetes Atlas. 2007. Available on: Scholar
  10. 10.
    Mlinar B, Marc J, Janez A et al. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007; 375(1–2):20–35.CrossRefPubMedGoogle Scholar
  11. 11.
    World Health Organization, FAO Expert Consultation. Diet, nutrition and the prevention of chronic diseases. 2003. WHO Technical Report Series.Google Scholar
  12. 12.
    Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer. Eur J Intern Med 2000; 11(5):245–252.CrossRefPubMedGoogle Scholar
  13. 13.
    Hu FB, Manson JE, Liu S et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91(6):542–547.CrossRefPubMedGoogle Scholar
  14. 14.
    Shoff SM, Newcomb PA. Diabetes, body size and risk of endometrial cancer. Am J Epidemiol 1998; 148(3):234–240.PubMedGoogle Scholar
  15. 15.
    Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80(11):1830–1837.CrossRefPubMedGoogle Scholar
  16. 16.
    Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007; 120(9):1993–1998.CrossRefPubMedGoogle Scholar
  17. 17.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4(8):579–591.CrossRefPubMedGoogle Scholar
  18. 18.
    Bergstrom A, Pisani P, Tenet V et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91(3):421–430.CrossRefPubMedGoogle Scholar
  19. 19.
    Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348(17):1625–1638.CrossRefPubMedGoogle Scholar
  20. 20.
    Strickler HD, Wylie-Rosett J, Rohan T et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001; 3(2):263–274.CrossRefPubMedGoogle Scholar
  21. 21.
    International Agency for Research on Cancer. Globocan 2002; Cancer Epidemiology Database. Intenational Agency for Research on Cancer 2002.Google Scholar
  22. 22.
    Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15(5):872–878.CrossRefPubMedGoogle Scholar
  23. 23.
    Rubenstein JH, Davis J, Marrero JA et al. Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 2005; 22(3):267–271.CrossRefPubMedGoogle Scholar
  24. 24.
    Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89(18):1360–1365.CrossRefPubMedGoogle Scholar
  25. 25.
    Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia and gastric noncardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005; 16(3):285–294.CrossRefPubMedGoogle Scholar
  26. 26.
    MacInnis RJ, English DR, Hopper JL et al. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006; 118(10):2628–2631.CrossRefPubMedGoogle Scholar
  27. 27.
    Khan M, Mori M, Fujino Y et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev 2006; 7(2):253–259.PubMedGoogle Scholar
  28. 28.
    Inoue M, Iwasaki M, Otani T et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166(17):1871–1877.CrossRefPubMedGoogle Scholar
  29. 29.
    Zendehdel K, Nyren O, Ostenson CG et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95(23):1797–1800.PubMedGoogle Scholar
  30. 30.
    Rennert G. Prevention and early detection of colorectal cancer-new horizons. Recent Results Cancer Res 2007; 174:179–187.CrossRefPubMedGoogle Scholar
  31. 31.
    Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006; 17(3):145–156.CrossRefPubMedGoogle Scholar
  32. 32.
    Sturmer T, Buring JE, Lee IM et al. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomarkers Prev 2006; 15(12):2391–2397.CrossRefPubMedGoogle Scholar
  33. 33.
    Ahmed RL, Schmitz KH, Anderson KE et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107(1):28–36.CrossRefPubMedGoogle Scholar
  34. 34.
    Bianchini F, Kaaks R, Vainio H. Overweight, obesity and cancer risk. Lancet Oncol 2002; 3(9):565–574.CrossRefPubMedGoogle Scholar
  35. 35.
    Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97(22):1679–1687.PubMedGoogle Scholar
  36. 36.
    Weiderpass E, Gridley G, Persson I et al. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997; 71(3):360–363.CrossRefPubMedGoogle Scholar
  37. 37.
    Will JC, Galuska DA, Vinicor F et al. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998; 147(9):816–825.PubMedGoogle Scholar
  38. 38.
    Limburg PJ, Vierkant RA, Fredericksen ZS et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006; 101(8):1872–1879.CrossRefPubMedGoogle Scholar
  39. 39.
    Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005; 4(2):173–177.PubMedGoogle Scholar
  40. 40.
    El Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4(3):369–380.CrossRefPubMedGoogle Scholar
  41. 41.
    Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88(20):1472–1477.CrossRefPubMedGoogle Scholar
  42. 42.
    Davila JA, Morgan RO, Shaib Y et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54(4):533–539.CrossRefPubMedGoogle Scholar
  43. 43.
    La Vecchia C, Negri E, Franceschi S et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70(5):950–953.PubMedGoogle Scholar
  44. 44.
    Lai MS, Hsieh MS, Chiu YH et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43(6):1295–1302.CrossRefPubMedGoogle Scholar
  45. 45.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118(7):1591–1602.CrossRefPubMedGoogle Scholar
  46. 46.
    Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 2007; 96(9):1457–1461.PubMedGoogle Scholar
  47. 47.
    Swerdlow AJ, Laing SP, Qiao Z et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005; 92(11):2070–2075.CrossRefPubMedGoogle Scholar
  48. 48.
    Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004; 59(2):99–111.PubMedGoogle Scholar
  49. 49.
    Berrington dG, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003; 89(3):519–523.CrossRefGoogle Scholar
  50. 50.
    Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129(2):504–511.PubMedGoogle Scholar
  51. 51.
    Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92(11):2076–2083.CrossRefPubMedGoogle Scholar
  52. 52.
    Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273(20):1605–1609.CrossRefPubMedGoogle Scholar
  53. 53.
    Samanic C, Chow WH, Gridley G et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006; 17(7):901–909.CrossRefPubMedGoogle Scholar
  54. 54.
    Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995; 4(8):807–811.PubMedGoogle Scholar
  55. 55.
    Adami HO, McLaughlin J, Ekbom A et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2(5):307–314.CrossRefPubMedGoogle Scholar
  56. 56.
    Ragozzino M, Melton LJ III, Chu CP et al. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982; 35(1):13–19.CrossRefPubMedGoogle Scholar
  57. 57.
    Hall GC, Roberts CM, Boulis M et al. Diabetes and the risk of lung cancer. Diabetes Care 2005; 28(3):590–594.CrossRefPubMedGoogle Scholar
  58. 58.
    Hanbali A, Al Khasawneh K, Cole-Johnson C et al. Protective effect of diabetes against metastasis in patients with nonsmall cell lung cancer. Arch Intern Med 2007; 167(5):513.CrossRefPubMedGoogle Scholar
  59. 59.
    Gallus S, Naldi L, Martin L et al. Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res 2006; 16(1):83–87.CrossRefPubMedGoogle Scholar
  60. 60.
    Chuang TY, Lewis DA, Spandau DF. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: a pilot study. Br J Dermatol 2005; 153(3):552–557.CrossRefPubMedGoogle Scholar
  61. 61.
    Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006; 166(21):2395–2402.CrossRefPubMedGoogle Scholar
  62. 62.
    Tehard B, Clavel-Chapelon F. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. Int J Obes (Lond) 2006; 30(1):156–163.CrossRefGoogle Scholar
  63. 63.
    Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev 2006; 7(4):333–340.CrossRefPubMedGoogle Scholar
  64. 64.
    Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2(3):133–140.CrossRefPubMedGoogle Scholar
  65. 65.
    Key TJ, Appleby PN, Reeves GK et al. Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95(16):1218–1226.PubMedCrossRefGoogle Scholar
  66. 66.
    Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003; 45(1):1–16.CrossRefPubMedGoogle Scholar
  67. 67.
    Morimoto LM, White E, Chen Z et al. Obesity, body size and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 2002; 13(8):741–751.CrossRefPubMedGoogle Scholar
  68. 68.
    La Vecchia C, Negri E, Franceschi S et al. Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer 1997; 75(3):441–444.PubMedGoogle Scholar
  69. 69.
    van der BB, Rutteman GR, Blankenstein MA et al. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 1988; 134(1):101–108.CrossRefGoogle Scholar
  70. 70.
    Mathieu MC, Clark GM, Allred DC et al. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997; 109(6):565–571.PubMedGoogle Scholar
  71. 71.
    Papa V, Belfiore A. Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 1996; 19(5):324–333.PubMedGoogle Scholar
  72. 72.
    Goodwin PJ, Ennis M, Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20(1):42–51.CrossRefPubMedGoogle Scholar
  73. 73.
    Yang G, Lu G, Jin F et al. Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(11):1207–1211.PubMedGoogle Scholar
  74. 74.
    Nyholm H, Djursing H, Hagen C et al. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab 1989; 69(5):946–949.CrossRefPubMedGoogle Scholar
  75. 75.
    Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women’s Heart and Health Study. Cancer Causes Control 2004; 15(3):267–275.CrossRefPubMedGoogle Scholar
  76. 76.
    Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007; 121(4):856–862.CrossRefPubMedGoogle Scholar
  77. 77.
    Wolf I, Sadetzki S, Catane R et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6(2):103–111.CrossRefPubMedGoogle Scholar
  78. 78.
    Wu AH, Yu MC, Tseng CC et al. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis 2007; 28(7):1561–1566.CrossRefPubMedGoogle Scholar
  79. 79.
    Modesitt SC, van NJ, Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 2005; 60(10):683–692.CrossRefPubMedGoogle Scholar
  80. 80.
    Chang SC, Lacey JV, Jr, Brinton LA et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2007; 16(4):723–730.CrossRefPubMedGoogle Scholar
  81. 81.
    Chia VM, Newcomb PA, Trentham-Dietz A et al. Obesity, diabetes and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 2007; 17(2):441–446.CrossRefPubMedGoogle Scholar
  82. 82.
    Weiderpass E, Persson I, Adami HO et al. Body size in different periods of life, diabetes mellitus, hypertension and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000; 11(2):185–192.CrossRefPubMedGoogle Scholar
  83. 83.
    Iatrakis G, Zervoudis S, Saviolakis A et al. Women younger than 50 years with endometrial cancer. Eur J Gynaecol Oncol 2006; 27(4):399–400.PubMedGoogle Scholar
  84. 84.
    Olsen CM, Green AC, Whiteman DC et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007; 43(4):690–709.CrossRefPubMedGoogle Scholar
  85. 85.
    Mori M, Saitoh S, Takagi S et al. A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. Asian Pac J Cancer Prev 2000; 1(4):269–276.PubMedGoogle Scholar
  86. 86.
    Weiderpass E, Ye W, Vainio H et al. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 2002; 13(8):759–764.CrossRefPubMedGoogle Scholar
  87. 87.
    Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17(1):5–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Littman AJ, White E, Kristal AR. Anthropometrics and Prostate Cancer Risk. Am J Epidemiol 2007; 165(11):1271–1279.CrossRefPubMedGoogle Scholar
  89. 89.
    Moyad MA. Is obesity a risk factor for prostate cancer and does it even matter? A hypothesis and different perspective. Urology 2002; 59(4A Suppl):41–50.CrossRefPubMedGoogle Scholar
  90. 90.
    Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47(6):1071–1078.CrossRefPubMedGoogle Scholar
  91. 91.
    Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(11):2056–2062.CrossRefPubMedGoogle Scholar
  92. 92.
    Calton BA, Chang SC, Wright ME et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18(5):493–503.CrossRefPubMedGoogle Scholar
  93. 93.
    Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005; 16(9):1055–1058.CrossRefPubMedGoogle Scholar
  94. 94.
    Weiderpass E, Ye W, Vainio H et al. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002; 102(3):258–261.CrossRefPubMedGoogle Scholar
  95. 95.
    Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility and renal cell cancer risk: a review. Cancer Invest 2005; 23(3):240–255.CrossRefPubMedGoogle Scholar
  96. 96.
    Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 2004; 160(12):1168–1176.CrossRefPubMedGoogle Scholar
  97. 97.
    Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176(6 Pt 1):2353–2358.CrossRefPubMedGoogle Scholar
  98. 98.
    Lindblad P, Chow WH, Chan J et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42(1):107–112.CrossRefPubMedGoogle Scholar
  99. 99.
    Washio M, Mori M, Khan M et al. Diabetes mellitus and kidney cancer risk: The results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol 2007; 14(5):393–397.CrossRefPubMedGoogle Scholar
  100. 100.
    Holick CN, Giovannucci EL, Stampfer MJ et al. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 2007; 120(1):140–146.CrossRefPubMedGoogle Scholar
  101. 101.
    Larsson SC, Orsini N, Brismar K et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12):2819–2823.CrossRefPubMedGoogle Scholar
  102. 102.
    Kravchick S, Gal R, Cytron S et al. Increased incidence of diabetes mellitus in the patients with transitional cell carcinoma of urinary bladder. Pathol Oncol Res 2001; 7(1):56–59.CrossRefPubMedGoogle Scholar
  103. 103.
    Dal Maso L, La Vecchia C, Franceschi S et al. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 2000; 11(2):137–144.CrossRefGoogle Scholar
  104. 104.
    Iribarren C, Haselkorn T, Tekawa IS et al. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 2001; 93(5):745–750.CrossRefPubMedGoogle Scholar
  105. 105.
    Skibola CF. Obesity, diet and risk of nonHodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007; 16(3):392–395.CrossRefPubMedGoogle Scholar
  106. 106.
    Larsson SC, Wolk A. Obesity and risk of nonHodgkin’s lymphoma: A meta-analysis. Int J Cancer 2007; 121(7):1564–1570.CrossRefPubMedGoogle Scholar
  107. 107.
    US Census Bureau; population census. IDB data access-display mode. Available on: http://www.census. gov/ipc/www/idbprint.htmlGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  • Anette Hjartåker
    • 2
  • Hilde Langseth
    • 2
  • Elisabete Weiderpass
    • 1
  1. 1.Cancer Registry of NorwayOsloNorway
  2. 2.Department of Etiological ResearchCancer Registry of NorwayOsloNorway

Personalised recommendations